CA2734208C - Mitochondrially delivered anti-cancer compounds - Google Patents

Mitochondrially delivered anti-cancer compounds Download PDF

Info

Publication number
CA2734208C
CA2734208C CA2734208A CA2734208A CA2734208C CA 2734208 C CA2734208 C CA 2734208C CA 2734208 A CA2734208 A CA 2734208A CA 2734208 A CA2734208 A CA 2734208A CA 2734208 C CA2734208 C CA 2734208C
Authority
CA
Canada
Prior art keywords
cells
compound
cancer
pro
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2734208A
Other languages
English (en)
French (fr)
Other versions
CA2734208A1 (en
Inventor
Jiri Neuzil
Stephen John Ralph
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancure Ltd
Original Assignee
Cancure Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008901261A external-priority patent/AU2008901261A0/en
Application filed by Cancure Ltd filed Critical Cancure Ltd
Publication of CA2734208A1 publication Critical patent/CA2734208A1/en
Application granted granted Critical
Publication of CA2734208C publication Critical patent/CA2734208C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2734208A 2008-03-14 2009-03-16 Mitochondrially delivered anti-cancer compounds Active CA2734208C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2008901261 2008-03-14
AU2008901261A AU2008901261A0 (en) 2008-03-14 Mitochondrially Delivered Anti-Cancer Compounds
PCT/AU2009/000312 WO2009111846A1 (en) 2008-03-14 2009-03-16 Mitochondrially delivered anti-cancer compounds

Publications (2)

Publication Number Publication Date
CA2734208A1 CA2734208A1 (en) 2009-09-17
CA2734208C true CA2734208C (en) 2018-01-09

Family

ID=41064682

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2734208A Active CA2734208C (en) 2008-03-14 2009-03-16 Mitochondrially delivered anti-cancer compounds

Country Status (7)

Country Link
US (2) USRE47300E1 (https=)
EP (1) EP2265623B1 (https=)
JP (1) JP5616798B2 (https=)
KR (1) KR101642157B1 (https=)
CA (1) CA2734208C (https=)
NZ (1) NZ602579A (https=)
WO (1) WO2009111846A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103764026B (zh) 2011-04-14 2016-10-19 艾伦斯生物科技有限公司 用于肝细胞癌的诊断、预后、监测和治疗的方法
WO2012174287A1 (en) * 2011-06-15 2012-12-20 The Board Of Regents Of The University Of Texas System Luminescent nanoparticle compositions
HK1200459A1 (en) 2011-09-19 2015-08-07 Gencia Corporation Modified creatine compounds
WO2013181488A2 (en) * 2012-06-01 2013-12-05 The Ohio State University Research Foundation Inhibition of leukemic stem cells by pp2a activating agents
PT2989110T (pt) * 2013-04-24 2018-11-15 Jira­ Neuzil Derivados de tamoxifeno para o tratamento de doenças neoplásicas, especialmente com nível elevado de proteína her2
US10953110B2 (en) 2014-04-25 2021-03-23 Board Of Regents, The University Of Texas System Dual emissive metal nanoparticles as ratiometric pH indicators
WO2016144637A1 (en) * 2015-03-06 2016-09-15 The Children's Hospital Of Philadelphia Tocopheryloxyacetate ester-based co-drug conjugates
CZ307146B6 (cs) * 2015-03-31 2018-02-07 Kkcg Se Trifenylfosfoniové analogy biguanidu, způsob jejich přípravy a jejich použití jako léčiva
US20180318324A1 (en) 2015-11-04 2018-11-08 Prescient Pharma Llc Anti-aging compositions and methods for using same
KR102361131B1 (ko) * 2020-02-25 2022-02-10 경희대학교 산학협력단 항생제 내성 균주에 대해 항균활성을 갖는 항균용 조성물
TW202233246A (zh) * 2020-10-22 2022-09-01 南韓商白雁生物技術公司 含有抗癌劑之粒線體及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069208A1 (en) * 1997-11-25 2003-04-10 University Of Otago Mitochondrially targeted antioxidants
US6331532B1 (en) * 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
KR100847678B1 (ko) 2000-02-11 2008-07-23 리서치 디벨럽먼트 파운데이션 토코페롤, 토코트리에놀, 다른 크로만 및 측쇄 유도체, 및이들의 용도
AUPQ605800A0 (en) * 2000-03-06 2000-03-30 Silverbrook Research Pty Ltd Printehead assembly
WO2002093063A1 (en) * 2001-05-17 2002-11-21 Imperial College Innovations Limited Production and processing plant with a rigid pipe portion curving in three dimensions
BRPI0413742B8 (pt) 2003-08-22 2021-05-25 Antipodean Pharmaceuticals Inc composto antioxidante quimicamente estável, composição farmacêutica, método de redução do estresse oxidativo em uma célula in vitro e métodos de preparo e de síntese do referido composto antioxidante
CN1925853B (zh) * 2004-07-28 2011-01-26 陈献 琥珀酸α-生育酚酯及其类似物和盐的稳定注射组合物
KR100556527B1 (ko) * 2004-11-04 2006-03-06 삼성전자주식회사 트렌치 소자 분리막 형성 방법 및 불휘발성 메모리 장치의제조 방법
WO2006094203A1 (en) 2005-03-02 2006-09-08 Northeastern University Mitochondriotropic phospholipid vesicles
RU2318500C2 (ru) 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
NZ575920A (en) 2006-09-15 2012-08-31 Stephen John Ralph Pro-oxidant anti-cancer compounds
JP4930026B2 (ja) * 2006-12-13 2012-05-09 富士ゼロックス株式会社 積層体、無端状ベルト、定着装置及び画像形成装置
DE102007025423A1 (de) 2007-05-30 2008-12-04 Friedrich-Schiller-Universität Jena Triphenylphosphonium-Derivate zum gezielten Transport und Freisetzen von Substanzen in Mitochondrien sowie Verfahren zu deren Verwendung

Also Published As

Publication number Publication date
JP5616798B2 (ja) 2014-10-29
EP2265623A4 (en) 2014-01-01
AU2009225261A1 (en) 2009-09-17
JP2011513437A (ja) 2011-04-28
CA2734208A1 (en) 2009-09-17
NZ602579A (en) 2013-12-20
US20110105437A1 (en) 2011-05-05
US8598145B2 (en) 2013-12-03
EP2265623B1 (en) 2016-07-13
WO2009111846A4 (en) 2009-11-05
USRE47300E1 (en) 2019-03-19
EP2265623A1 (en) 2010-12-29
WO2009111846A1 (en) 2009-09-17
KR101642157B1 (ko) 2016-07-22
KR20100135803A (ko) 2010-12-27

Similar Documents

Publication Publication Date Title
CA2734208C (en) Mitochondrially delivered anti-cancer compounds
Jara et al. Antiproliferative and uncoupling effects of delocalized, lipophilic, cationic gallic acid derivatives on cancer cell lines. Validation in vivo in singenic mice
Liao et al. Involvement of the ERK signaling pathway in fisetin reduces invasion and migration in the human lung cancer cell line A549
Munteanu et al. Synthesis, characterization, cytotoxic activity, and metabolic studies of ruthenium (II) polypyridyl complexes containing flavonoid ligands
Aroui et al. A novel platinum–maurocalcine conjugate induces apoptosis of human glioblastoma cells by acting through the ROS-ERK/AKT-p53 pathway
US8410056B2 (en) Pro-oxidant anti-cancer compounds
Xu et al. Potent half-sandwich Ru (Ⅱ) N^ N (aryl-BIAN) complexes: Lysosome-mediated apoptosis, in vitro and in vivo anticancer activities
Sukamporn et al. Damnacanthal and its nanoformulation exhibit anti-cancer activity via cyclin D1 down-regulation
Kwak et al. Blood-brain barrier-permeable fluorone-labeled dieckols acting as neuronal ER stress signaling inhibitors
Pang et al. Reactive oxygen species-responsive nanococktail with self-amplificated drug release for efficient co-delivery of paclitaxel/cucurbitacin B and synergistic treatment of gastric cancer
Chen et al. Improved stability and targeted cytotoxicity of epigallocatechin-3-gallate palmitate for anticancer therapy
Lee et al. Strategy for traceless codrug delivery with platinum (IV) prodrug complexes using self-immolative linkers
Huang et al. Glycyrrhetinic acid as a hepatocyte targeting ligand-functionalized platinum (IV) complexes for hepatocellular carcinoma therapy and overcoming multidrug resistance
Li et al. Formulation of the novel structure curcumin derivative–loaded solid lipid nanoparticles: synthesis, optimization, characterization and anti-tumor activity screening in vitro
Checker et al. Chemopreventive and anticancer effects of plumbagin: Novel mechanism (s) via modulation of cellular redox
Liu et al. An EGCG-mediated self-assembled micellar complex acts as a bioactive drug carrier
Gudyka et al. Differential effects of soy isoflavones on the biophysical properties of model membranes
Wang et al. Fluoxetine-Conjugated Platinum (IV) Prodrugs Targeting eEF2K and Conquering Multidrug Resistance against Triple-Negative Breast Cancer
AU2009225261B2 (en) Mitochondrially delivered anti-cancer compounds
Vo et al. Exploring Flavonoids as Regulators of MMP‐2 and MMP‐9 in Cancer Pathogenesis
Dey et al. Poly-β-thioester-based cross-linked nanocarrier for cancer cell selectivity over normal cells and cellular apoptosis by triggered release of parthenolide, an anticancer drug
Dong et al. Vitamin E analogues as prototypic mitochondria-targeting anti-cancer agents
Crespo et al. Solubility-Improved and Antitumor Activity of (-)-Cannabidiol Conjugates
Zingg Wu et al., 2017) could play a role in other diseases, such as age-dependent macular degeneration or Alzheimer's disease (Ohno-Matsui, 2011).
Rodriguez et al. Melatonin: Relationship with Cell Death

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140311

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251023